- Home
- ASLE vs DCTH Comparison
ASLE vs DCTH Comparison
Compare ASLE & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASLE | DCTH |
|---|---|---|
| Founded | 2008 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.0M | 289.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ASLE | DCTH |
|---|---|---|
| Price | $6.95 | $10.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.00 | ★ $22.60 |
| AVG Volume (30 Days) | 417.3K | ★ 748.8K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.11 | 0.03 |
| Revenue | ★ $339,090,000.00 | $79,603,000.00 |
| Revenue This Year | $1.35 | $131.97 |
| Revenue Next Year | $19.09 | $38.84 |
| P/E Ratio | ★ $62.29 | $300.53 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $5.56 | $8.12 |
| 52 Week High | $9.12 | $18.23 |
Technical Indicators
Market Signals| Indicator | ASLE | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 56.07 |
| Support Level | $6.33 | $9.59 |
| Resistance Level | $7.11 | $10.65 |
| Average True Range (ATR) | 0.16 | 0.45 |
| MACD | 0.11 | 0.13 |
| Stochastic Oscillator | 82.50 | 63.00 |
Price Performance
Historical ComparisonAbout ASLE AerSale Corporation
AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.